Neuroelectrics announces positive results for treatment of medication-Resistant epilepsy using Starstim™

shop-mgr2023-12-07T14:32:59+08:00 At the recent American Epilepsy Society Annual Meeting in New Orleans, Neuroelectrics Corporation presented positive results from its clinical trial treating patients with drug resistant epilepsy with Starstim a device that uses mild electric currents applied on the scalp to calm abnormal activity of the brain. Of the seventeen patients that completed the study, treatment with Neuroelectrics’ Starstim device resulted in a reduction in seizure frequency of at least 40% from baseline in 75% of the patients, measured eight weeks after treatment. Also, no device-related adverse events were reported during the study. Neuroelectrics sponsored the FDA-approved investigational device study of its Starstim product (NCT02866240) at Boston Children’s Hospital, with adult...

FDA Greenlights Neuroelectrics To Help Patients With Major Depression At Home Amidst Covid-19 Restrictions

shop-mgr2022-12-28T10:18:59+08:00 Neuroelectrics has developed a novel platform to provide personalized therapies for brain disorders using non-invasive brain stimulation Neuroelectrics has received approval by the FDA to conduct a clinical trial of brain stimulation therapy at home through telemedicine for patients with Major Depressive Depression (MDD) By moving into MDD, Neuroelectrics expands their pipeline and current suite of neurodegenerative products into neuropsychiatry Cambridge, MA, USA and Barcelona, SP, May 15th: Today Neuroelectrics announced that the FDA has approved the Investigational Device Exemption supplemental protocol study submitted by Neuroelectrics to help patients with Major Depression Disorder (MDD) that cannot access their current non-invasive brain stimulation treatment (rTMS*...